Longeveron (LGVN) Cash from Investing Activities (2020 - 2026)
Longeveron (LGVN) posted quarterly Cash from Investing Activities of -$20000.0 for Q1 2026, up 86.67% year-over-year from -$10714.3 in Q1 2025, and up 68.75% quarter-over-quarter from -$64000.0 in Q4 2025.
Longeveron (LGVN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Longeveron's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$20000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 86.67% year-over-year to -$20000.0; the TTM figure through Mar 2026 stood at -$465000.0 (up 42.16% YoY), while the FY2025 annual figure was -$595000.0, up 7.03% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$20000.0, up from -$64000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $3.8 million in Q3 2023, with the low at -$2.4 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$53000.0 (2024), against an average of $367882.4.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities soared 374.39% in 2023, then plunged 1171.43% in 2025.
- Longeveron's Cash from Investing Activities stood at -$570000.0 in 2022, then jumped by 374.39% to $1.6 million in 2023, then sank by 107.86% to -$123000.0 in 2024, then surged by 47.97% to -$64000.0 in 2025, then jumped by 68.75% to -$20000.0 in 2026.
- Business Quant data shows LGVN's Cash from Investing Activities at -$20000.0 in Q1 2026, -$64000.0 in Q4 2025, and -$118000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -103,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -103,000.00 |
| Jun 30, 2026 | -103,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -64,000.00 |
| Dec 31, 2025 | -64,000.00 |
| Sep 30, 2025 | -118,000.00 |
| Sep 30, 2025 | -118,000.00 |
| Jun 30, 2025 | -263,000.00 |
| Jun 30, 2025 | -263,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Dec 31, 2024 | -123,000.00 |
| Dec 31, 2024 | -123,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |